PAR2/F2RL2 recombinant proteins and antibodies

Protease-activated receptor 2 (PAR2), encoded by F2RL2 gene, is a G-protein coupled receptor that belongs to the protease-activated receptor (PAR) family. It is widely expressed in various cell types, including endothelial cells, smooth muscle cells, immune cells, and the nervous system. PAR2 activates downstream signaling pathways upon binding with exogenous or endogenous proteases, such as coagulation factors, playing a crucial role in regulating a range of physiological processes, including inflammation, vascular function, pain perception, and immune responses. PAR2 has been implicated in a variety of diseases, especially in thrombosis, cardiovascular diseases, cancer, and neurodegenerative disorders, making it a highly regarded therapeutic target.

PAR2 can promote vasodilation, inflammatory cell recruitment, and thrombosis through its activated signaling pathways, which makes it a focus of research in cardiovascular and thrombotic diseases. Additionally, PAR2 is believed to play an important role in cancer metastasis, immune regulation within the tumor microenvironment, and neuroinflammatory responses. Therefore, PAR2 has become a critical target for drug development in areas such as thrombosis, cancer therapy, and anti-inflammatory treatments. Studies suggest that specific PAR2 agonists and antagonists are emerging as drug development hotspots.

Currently, drug development around PAR2 is primarily focused on cardiovascular diseases, cancer treatment, and pain management. Some pharmaceutical companies have developed PAR2 antagonists, which block PAR2 activation to reduce inflammation, improve symptoms of thrombotic diseases, and potentially alleviate conditions caused by excessive activation of PAR2. For example, PAR2 antagonists have shown potential in preclinical studies for combating atherosclerosis, acute coronary syndrome, and chronic inflammation. Moreover, PAR2’s role in immune evasion mechanisms in cancer has garnered significant attention, and some companies are exploring PAR2-targeted immunotherapy.

In terms of industry positioning, several biopharmaceutical companies have entered the field of PAR2-related drug development. For instance, some companies are developing PAR2 antagonists to be used in combination with existing antithrombotic drugs or immune checkpoint inhibitors, aiming to enhance therapeutic efficacy through multi-target therapies. Additionally, some companies are exploring PAR2 as a new target for treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

To assist in the development of drugs targeting PAR2, DIMA BIOTECH can now provide full-length PAR2 recombinant membrane protein developed by its nanodisc membrane protein platform. PAR2 nanodisc is an optimal solution for screening small molecules targeting PAR2 with its natural structure. Furthermore, DIMA BIOTECH has also prepared a PAR2 single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.